Intranasal Esketamine Clinical Data – Implications for Patients and Clinicians

Posted on: November 21, 2022
Last Updated: April 19, 2023

In this video, Dr Sanil Rege, consultant psychiatrist reviews the key clinical data for intranasal esketamine in the management of treatment-resistant depression including:

  • the onset of action and impact on depression symptoms 24 hours after dosing
  • 28-day response and remission rates
  • sustained response and prevention of relapse
  • safety and tolerability

Based on data from the TRANSFORM 2 and SUSTAIN 1 and SUSTAIN 2 studies, we discuss what these results contribute to clinical practice for both patients and clinicians.

Any topics in mental health you would like covered? We would love to hear from you! Get in touch by contacting us at